Vaccine designs can be renewed faster against mutations


Pointing out that Turkey has not produced human vaccines since the second half of the 1990s, Mandal noted that they have made significant gains in the Kovid-19 process at the point reached.

“Just as Turkey was an importer country in the defense industry and increased its localization rate from 15 percent to 70 percent, now there is a potential not only for Kovid-19, but for the future, Turkey can become a global player in both vaccines and drugs.” Mandal stated that their biggest assurances are Turkish scientists.

Mandal pointed out that there is a scattered structure at the research point in Turkey, “The TÜBİTAK MAM Genetic Engineering and Biotechnology Institute we are in is a coordinating structure. In this period, our most important difference compared to the world is that we coordinated this dispersed structure through this center.” he spoke.

“Our vaccines are not the same as those found abroad, so we do not copy.”

Mandal stated that when Kovid-19 started, they created a platform where 49 different organizations and 436 researchers came together with the new method for vaccine and drug development in Turkey under the coordination of Minister of Industry and Technology Mustafa Varank, and stated that the researchers used this infrastructure.

Mandal stated that they are experiencing a cultural change and that the researchers and young students work day and night with the spirit of mobilization.

“Other countries had experience in other vaccine development studies due to SARS and MERS at the clinical stage. If we started from our own cell in a period of 1 year, maybe a period of 5 to 10 years during this study, and now we have come to phase studies. an important success. We are proceeding in a planned way in the follow-up. Phase 1, phase 2 and phase 3. “

Emphasizing that 436 researchers worked in 17 projects, Mandal said, “7 of these are vaccines, 10 of them are drug studies and treatment methods. None of the 7 vaccine studies are similar, each is a different type of vaccine. Inactive but innovative inactive, which we call the traditional vaccine. Our other 6 vaccines are biotechnological vaccines and they are not the same as those abroad. So we do not make a copy. The designs developed by our professors at the point of investment for the future are realized with an innovative design in the world. In this sense, 3 of the 7 vaccines are at the forefront. One is a vaccine based on virus-like particles (VLP), the other is an innovative inactive vaccine, and one is an adenovirus-type vaccine. ” used the expressions.

“Vaccine production is possible in our infrastructures in Turkey”

The founding partner of the German biotech firm BioNTech, Prof. Dr. Stating that they have been in contact with Uğur Şahin since the first period of the epidemic, Mandal stated that he congratulated him as a scientist.

Explaining that their communication with Şahin is at the point of what they can do together, Mandal said, “Unfortunately, a statement made by our teacher in German recently caused a different interpretation on social media. we are in. ‘ BioNTech states that the facility cannot be established before the end of 2022 at the point of establishing a facility, but because of this, BioNTech does not currently have vaccine production in our infrastructure in Turkey. . ” he spoke.

Mandal stated that TÜBİTAK is a place where production is carried out on a pilot scale in cell phase studies, but it is not a production center, adding that their production center is companies with the necessary competence and that there are competent companies in this sense in Turkey.